Dr. Yongping Shao (邵永平)

Laboratory of cell signaling transduction

email: yongping.shao@mail.xjtu.edu.cn

Education

09/2001-05/2007 Ph.D in Molecular Biology, State University of New York at Albany, USA

09/1997-06/2000 M.S. in Botany, Fudan University

09/1993-06/1997 B.S. in Biology, Fudan University

Employment

12/2016–now Professor, Frontier Institute of Science and Technology (FIST), Xi’an Jiaotong University, China

07/2013–11/2016 Group Leader I, Center for Translational Medicine, Frontier Institute of Science and Technology (FIST), Xi’an Jiaotong University, China

12/2008–05/2013 Postdoctoral Fellow, Kimmel Cancer Center, Thomas Jefferson University

05/2007–11/2008 Postdoctoral Associate, State University of New York at Albany

Award

2011 Jefferson Postdoctoral Research Symposium Poster Presentation Award

2011 Jefferson Collage of Graduate Study Postdoctoral Travel Fellowship

2010 “Outrun the Sun” National Melanoma Research Scholar Award

2007 Distinguished Doctoral Dissertation Award, SUNY Albany

2004 “Dr. Peter Marfey” Book Scholarship, SUNY Albany

Research Interest

1. Mechanisms of Resistance to targeted therapy in human melanoma.

Acquired and/or adaptive resistance to small molecule inhibitor drugs represents a major hurdle for improvement of clinical benefits in targeted cancer therapy. Using human melanoma as a cancer model, we are interested in the mechanisms of the development of acquired or adaptive resistance to RAF or MEK inhibitors.

2. The function and regulatory mechanism of protein posttranslational modification.

Protein posttranslational modification plays important roles in the regulation of protein functions and in cancer development. Using a combinational approach of protein chemical synthesis, mass spectrometry, crystallography etc, we aim to identify novel posttranslational modifications of several cancer-related proteins such as SOX10, CIC and β-Catenin, investigate their biological implications in cancer development as well as their regulation modes.

3. DC-based cellular immunotherapy platform

Cellular immunotherapy is an innovative treatment approach that harness the patient’s own immune system to fight cancer. Dendritic cells (DCs) are the most potent antigen presenting cells in human body and can be potentially used as tumor-antigen presenter to activate autologous T cells that eliminate cancer cells. We attempt to establish immortalized DC cell lines as a platform for rapid and convenient activation of autologous cytotoxic T lymphocytes to treat infectious diseases and cancer.

Publications

1. He W^*, Yan J^*, Sui F, Wang S, Su X, Qu Y, Yang Q, Guo H, Ji M, Lu W,Shao Y^#,Hou P^#. Turning a Luffa Protein into a Self-Assembled Biodegradable Nanoplatform for Multitargeted Cancer Therapy. 2018.ACS Nano. 12(11):11664-11677. doi: 10.1021/acsnano.8b07079.

2. Xu D*, Liao C*, Zhang B, Tolbert D, He W, Dai Z, Zhang W, Yuan W, Pazgier M, Liu J, Yu J, Sansonetti P, Bevins C,Shao Y^#,Lu W^#. Human enteric α-Defensin 5 promotes Shigella infection by enhancing bacterial adhesion and invasion. 2018.Immunity.pii: S1074-7613(18)30183-3. (FEATURED ARTICLE)

3. Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Ren Y, Purwin T, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J^#,Shao Y^#. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. 2018.Nat Commun.9(1):28. doi: 10.1038/s41467-017-02354-x.

4. Jia J, Liu F, Luo S, Li C, Yang J, Wang X, Wang N, Lai B, Lei T, Wang Q, Xiao S,Shao Y^#,Zheng Y^#. Yes-associated protein contributes to the development of human cutaneous squamous cell carcinoma via activation of Ras. 2016.J Invest Dermatol.136(6):1267-77.

5. Shao Y, Le K, Cheng H, Aplin AE^#. NFκB-Regulation of c-FLIP Promotes TNFα-Mediated RAF Inhibitor Resistance in Melanoma. 2015.J Invest Dermatol.135(7):1839-48.

6. Shao Yand Aplin AE^#. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. 2012.Cell Death Differ.19:2029-39.

7. Shao Yand Aplin AE^#. ERK-regulated phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. 2012.Cell Death Dis.3(1):e253.

8. Shao Yand Aplin AE^#. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. 2010.Cancer Res. 15; 70(16):6670-81.

9. Shao Yand Wang IN^#. Effect of late promoter activity on bacteriophage lambda fitness. 2009.Genetics.181(4):1467-75.

10. Shao Yand Wang IN^#. Bacteriophage adsorption rate and optimum lysis time. 2008.Genetics. 180(1):471-82.

11. Shao Y, Feldman-Cohen LS, Osuna R^#. Biochemical identification of base and phosphate contacts between Fis and a high affinity DNA binding site. 2008.J Mol Biol. 380(2):327-39.

12. Shao Y, Feldman-Cohen LS, Osuna R^#. Functional characterization of theEscherichia coliFis-DNA binding sequence.2008.J Mol Biol. 376(3):771-85.